接触免疫治疗斑秃患者的毛发再生结局:系统评价与荟萃分析
该系统评价与荟萃分析纳入45项研究共2227例斑秃患者,评估二苯环丙烯酮或方酸二丁酯接触免疫治疗的毛发再生率。任何毛发再生总体率为65.5%,完全再生率为32.3%;疾病范围≥50%、特应性病史和甲受累与较差疗效相关。
要点
- 任何毛发再生总体率为65.5%,斑秃亚组74.6%,全秃/普秃亚组54.5%。
- 完全再生率为32.3%,斑秃亚组24.9%,全秃/普秃亚组32.3%。
- 疾病范围≥50%(OR 3.05)、特应性病史(OR 1.61)、甲受累(OR 2.06)与较差疗效相关。
核心结论
- 接触免疫治疗斑秃的临床结局与多种因素相关,不同预期再生等级下毛发再生率存在显著差异。
- 定量汇总可能改善患者教育并提高治疗依从性和结局。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Embase和Cochrane Library截至2017年11月20日发表的文献。
- 纳入45项研究共2227例患者,纳入临床试验或观察性研究,将疾病亚组分为斑片状斑秃或全秃/普秃并报告毛发再生率。
- 排除联合治疗、非传统方案、病例系列或综述;因预期高异质性采用随机效应模型进行数据合成。
主要发现
- 任何毛发再生总体率为65.5%,斑片状斑秃亚组为74.6%,全秃/普秃亚组为54.5%。
- 完全再生率为32.3%,斑片状斑秃亚组为24.9%,全秃/普秃亚组为32.3%。
- 疾病范围≥50%(OR 3.05;95%CI 2.26-4.12)、特应性病史(OR 1.61;95%CI 1.03-2.50)、甲受累(OR 2.06;95%CI 1.26-3.36)与较差治疗结局相关。
- 复发率在接受维持治疗的患者中为38.3%,在未接受维持治疗的患者中为49.0%。
关键数值与推荐
- 主要结局为根据4级疗效标准判定的治疗性毛发再生率。
- 次要结局包括治疗相关不良事件发生率和复发率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Contact immunotherapy with diphenylcyclopropenone or squaric acid dibutyl ester is a preferred treatment for severe alopecia areata; however, the defined criteria for therapeutic hair regrowth and regrowth rate have been highly heterogeneous across studies. OBJECTIVE: To summarize the clinical outcomes of contact immunotherapy for alopecia areata according to standardized criteria for therapeutic hair regrowth and several prognostic factors. DATA SOURCE: A database search of MEDLINE, Embase, and Cochrane Library was performed for articles published before November 20, 2017, using the search terms areata, totalis, universalis, sensitizer, sensitization, immunotherapy, DPCP, diphenylcyclopropenone, diphencyprone, SADBE, and squaric. STUDY SELECTION: Clinical trials or observational studies that investigated contact immunotherapy for alopecia areata and subgrouped the disease into patchy alopecia or alopecia totalis/universalis and reported their hair regrowth rates were included, whereas studies that investigated combination therapy or nonconventional protocol and case series or reviews were excluded. DATA EXTRACTION AND SYNTHESIS: The following data were extracted from each of the studies included in this meta-analysis: study year and setting, sensitizer type, study population, study population composition by disease subtype, defined criteria for therapeutic hair regrowth, and regrowth rate of contact immunotherapy. The incidence of adverse effects and recurrence rate were also recorded. A random effects model was used for data synthesis because of the expected high heterogeneity of the included studies. MAIN OUTCOMES AND MEASURES: The main outcome was therapeutic hair regrowth rate according to the 4-grade criteria for therapeutic regrowth. Secondary outcomes included incidence of treatment-related adverse effects and recurrence rate. RESULTS: Forty-five studies comprising 2227 patients were analyzed. The overall rate of any hair regrowth was 65.5% among patients with alopecia areata (74.6% in the patchy alopecia and 54.5% in the alopecia totalis/universalis subgroups). However, the complete regrowth rate was 32.3% (24.9% in the patchy alopecia and 32.3% in the alopecia totalis/universalis subgroups). Disease extent of 50% or greater (odds ratio [OR], 3.05; 95% CI, 2.26-4.12), atopic history (OR, 1.61; 95% CI, 1.03-2.50), and nail involvement (OR, 2.06; 95% CI. 1.26-3.36) were associated with poorer therapeutic outcome. Recurrence rates were 38.3% among patients receiving maintenance treatment and 49.0% among those not receiving maintenance treatment. CONCLUSIONS AND RELEVANCE: Various factors were associated with the clinical outcomes of contact immunotherapy for alopecia areata, with significant differences in hair regrowth rates according to the level of expected therapeutic regrowth. Quantitative summarization may improve patient education and lead to better therapeutic adherence and outcomes.
引用
- Lee S, Kim BJ, Lee YB, et al. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis. JAMA Dermatol. 2018. PMID: 30073292. doi:10.1001/jamadermatol.2018.2312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。